Cisbio Bioassays has launched Chromoa, its chromogranin A enzyme-linked immunosorbent assay (ELISA) diagnostic tool. The new kit complements Cisbio’s existing chromogranin A radioimmunoassay (RIACT) kit and can be used by all laboratories for the detection and monitoring of neuroendocrine tumours.
Chromogranin A is an increasingly essential analyte for the detection and monitoring of such tumours as well as prostate cancer, which can evolve into an aggressive neuroendocrine form.
Chromoa offers the same reliable results but in an ELISA format. This new kit features a longer shelf life and offers easier stock management, making it a convenient time- and cost-saving alternative. Particularly suitable for laboratories that do not use radioactive kits, ELISA methods have been used for quantitative analysis for several decades and can be adopted by any laboratory.
www.iba-worldwide.com